Journal article · 2015 · Open access

Patient Preference for Lung and Colon Cancer Therapy in Germany

Katharina Schmidt, Kathrin Damm, JM von der Schulenburg

European Journal of Public Health, 25(suppl_3) · Published 1 October 2015 · DOI 10.1093/eurpub/ckv176.269

Open PDFView at the publisherCite this paper

In brief

“Patient Preference for Lung and Colon Cancer Therapy in Germany” is a 2015 journal article by Katharina Schmidt and 2 co-authors, published in European Journal of Public Health. OpenAlex counts 2 citations as of 22 November 2026. It is open access: the full text is free to read at European Journal of Public Health.

Citations
2
Most cited in
2016 (1)
Field-weighted impact
1.03
Authors
3

Abstract

Background There is a growing interest in patient-reported outcomes (PROs) to improve both pharmaceuticals and the treatment process. They are particularly relevant in oncology, where improvements in survival and response rates are marginal between the treatment options and severe side effects may occur. The aim of this study is to identify the chemotherapy treatment preferences of lung (LC) and colon cancer (CRC) patients. Methods The Discrete Choice Experiment (DCE) sets were derived based on guided qualitative interviews (n = 38). LC and CRC patients aged 18 years and older who received at least one cycle of chemotherapy are eligible for inclusion. Sociodemographic and quality of life data are collected. Descriptive statistics and multivariate regression methods (conditional logit and latent class models) are employed to identify potential bias trough group differences and determinants of patients` therapy preferences. Results The preliminary sample comprises of 57 patients (32 LC, 25 CRC) with a median age of 64 years. Five attributes were identified for inclusion in the DCE based on the pilot study: survival, guidance through therapy, appearance, physical capacity as well as food intake and digestion. The conditional logit model for choice of therapy showed a significant association with survival (Odds Ratio = 8.31, p < 0.001), physical capacity (OR = 0.46, p < 0.001), food intake and digestion (OR = 0.45, p < 0.01) as well as appearance (OR = 0.81, p = 0.05). Additional analyses will be conducted after completion of patient recruitment. Discussion Overall survival seems to be the most important attribute for patients. These findings are consistent with current state of research. Further results will be updated during the next months until completion of the recruitment of 250 LC and 250 CRC patients. A Limitation of this study is the regional focus on specialized clinics in Lower Saxony. However, first recommendations for patient oriented improvement of therapy can be drawn. Key messages Therapy for colon and lung cancer patients should involve patient preferences Overall Survival is the most important attribute for the patients in the therapy

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Schmidt, K., Damm, K., & von der Schulenburg, J. (2015). Patient Preference for Lung and Colon Cancer Therapy in Germany. European Journal of Public Health, 25(suppl_3). https://doi.org/10.1093/eurpub/ckv176.269

MLA 9

Schmidt, Katharina, et al. “Patient Preference for Lung and Colon Cancer Therapy in Germany.” European Journal of Public Health, vol. 25, no. suppl_3, 2015. https://doi.org/10.1093/eurpub/ckv176.269.

Chicago

Schmidt, Katharina, Kathrin Damm, and JM von der Schulenburg. 2015. “Patient Preference for Lung and Colon Cancer Therapy in Germany.” European Journal of Public Health 25 (suppl_3). https://doi.org/10.1093/eurpub/ckv176.269.

Harvard

Schmidt, K., Damm, K. and von der Schulenburg, J. (2015) ‘Patient Preference for Lung and Colon Cancer Therapy in Germany’, European Journal of Public Health, 25(suppl_3). doi:10.1093/eurpub/ckv176.269.

IEEE

K. Schmidt, K. Damm, and J. von der Schulenburg, “Patient Preference for Lung and Colon Cancer Therapy in Germany,” European Journal of Public Health, vol. 25, no. suppl_3, 2015, doi: 10.1093/eurpub/ckv176.269.

BibTeX

@article{schmidt2015patient,
  title     = {{Patient Preference for Lung and Colon Cancer Therapy in Germany}},
  author    = {Schmidt, Katharina and Damm, Kathrin and von der Schulenburg, JM},
  journal   = {European Journal of Public Health},
  year      = {2015},
  volume    = {25},
  number    = {suppl_3},
  doi       = {10.1093/eurpub/ckv176.269},
  url       = {https://doi.org/10.1093/eurpub/ckv176.269}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Environmental Valuation

  • patient preferences
  • lung cancer
  • colon cancer
  • chemotherapy
  • patient-reported outcomes
  • discrete choice experiment
  • overall survival
  • treatment side effects

Work with this paper

Most-cited papers in Economics, Econometrics and Finance

All highly cited Economics, Econometrics and Finance papers

Questions about this paper

How do I cite this paper in APA style?

Schmidt, K., Damm, K., & von der Schulenburg, J. (2015). Patient Preference for Lung and Colon Cancer Therapy in Germany. European Journal of Public Health, 25(suppl_3). https://doi.org/10.1093/eurpub/ckv176.269

How many times has this paper been cited?

2 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at European Journal of Public Health: sign in and open the PDF from this page.

Who wrote this paper?

Katharina Schmidt, Kathrin Damm, JM von der Schulenburg.

What is the DOI of this paper?

10.1093/eurpub/ckv176.269, permanently at https://doi.org/10.1093/eurpub/ckv176.269. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.